Valink Therapeutics logo

Valink Therapeutics

Discovering bispecific antibody drug-conjugates (BsADC) against cancer

Boston, US

BiotechTherapeuticsDrug discovery
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Meet the team2

The people behind Valink Therapeutics

Arne Scheu
Arne Scheu
Founder
LinkedIn profile
Irsyad Khairil
Irsyad Khairil
Founder
LinkedIn profile